ArriVent BioPharma (NASDAQ:AVBP) Receives Outperform Rating from Oppenheimer

Oppenheimer restated their outperform rating on shares of ArriVent BioPharma (NASDAQ:AVBP) in a report issued on Friday,Benzinga reports. They currently have a $50.00 price target on the stock, up from their prior price target of $44.00.

A number of other analysts also recently issued reports on AVBP. HC Wainwright lifted their price target on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the company a “buy” rating in a report on Friday. Truist Financial assumed coverage on shares of ArriVent BioPharma in a report on Tuesday, November 25th. They set a “buy” rating and a $43.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Wednesday, January 21st. BTIG Research assumed coverage on ArriVent BioPharma in a report on Wednesday, December 10th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ArriVent BioPharma has an average rating of “Moderate Buy” and a consensus price target of $41.11.

ArriVent BioPharma Stock Down 7.2%

AVBP stock traded down $1.82 during midday trading on Friday, hitting $23.43. The company’s stock had a trading volume of 1,788,123 shares, compared to its average volume of 393,931. ArriVent BioPharma has a 12 month low of $15.47 and a 12 month high of $27.22. The company has a 50 day moving average of $22.20 and a two-hundred day moving average of $20.92. The firm has a market capitalization of $967.19 million, a price-to-earnings ratio of -5.31 and a beta of 0.99.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, analysts anticipate that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Trading of ArriVent BioPharma

Several hedge funds have recently made changes to their positions in the business. Bessemer Group Inc. bought a new position in shares of ArriVent BioPharma in the 3rd quarter valued at about $26,000. Russell Investments Group Ltd. raised its position in ArriVent BioPharma by 9,747.6% during the third quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock valued at $38,000 after purchasing an additional 2,047 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of ArriVent BioPharma by 27.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after purchasing an additional 438 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of ArriVent BioPharma by 31.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after purchasing an additional 609 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in shares of ArriVent BioPharma in the 4th quarter worth approximately $57,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma News Summary

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.